Iruplinalkib
Phase 2Small molecule
Qilu Pharmaceutical Co., Ltd.Iruplinalkib is one of 110 small molecule programs targeting Lung Adenocarcinoma. It is currently in Phase 2.
4
Indications
6
Total Trials
5
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tabrecta
NovartisPhase 3
IL-2
FFate Therapeutics
Phase 3
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Iruplinalkib
Qilu Pharmaceutical Co., Ltd.Phase 2
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer2 trials
Lung Adenocarcinoma1 trial
Iruplinalkib1 trial
Postoperative Adjuvant Therapy1 trial
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07330076·28 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iruplinalkib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details